JP2018509423A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509423A5 JP2018509423A5 JP2017548144A JP2017548144A JP2018509423A5 JP 2018509423 A5 JP2018509423 A5 JP 2018509423A5 JP 2017548144 A JP2017548144 A JP 2017548144A JP 2017548144 A JP2017548144 A JP 2017548144A JP 2018509423 A5 JP2018509423 A5 JP 2018509423A5
- Authority
- JP
- Japan
- Prior art keywords
- immune complex
- subject
- immunoconjugate
- bladder
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010047814 Antigen-Antibody Complex Proteins 0.000 claims 12
- 108010027440 Immunoconjugates Proteins 0.000 claims 7
- 102000018748 Immunoconjugates Human genes 0.000 claims 7
- 210000003932 Urinary Bladder Anatomy 0.000 claims 5
- 206010005003 Bladder cancer Diseases 0.000 claims 4
- 108010077397 Pseudomonas aeruginosa toxA protein Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 230000003442 weekly Effects 0.000 claims 3
- 208000009458 Carcinoma in Situ Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 210000003205 Muscles Anatomy 0.000 claims 1
- 238000002679 ablation Methods 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 230000000717 retained Effects 0.000 claims 1
Claims (9)
- それを必要とする対象において、膀胱癌を処置する方法に使用するための免疫複合体であって、アミノ酸252−608からなるPseudomonas属外毒素Aの切断型形態に融合したscFvヒト化抗体4D5MOC−Bを含み、
1.前記免疫複合体が、前記対象に、少なくとも約6週連続の第1の投薬期間、週2回投与され、
2.その後、第2の投薬期間、前記免疫複合体が、少なくとも約6週連続の期間、週1回投与され、
3.その後、第3の投薬期間、前記免疫複合体が、隔週で週1回投与され、
4.前記免疫複合体が、前記第1の投薬期間に先立って、前記対象の膀胱から、経尿道切除を介してNMIBC腫瘍を除去された対象に投与される、免疫複合体。 - 前記膀胱癌が、非筋肉侵襲性膀胱癌(NMIBC)であり、前記NMIBCが、上皮内癌(CIS)、Ta、またはT1と分類される、請求項1に記載の免疫複合体。
- 前記免疫複合体の前記第1の投薬を施す前に、前記対象の膀胱から腫瘍が除去される、請求項1または2に記載の免疫複合体。
- 前記対象が、BCGおよび/またはインターフェロンで以前に処置されており、前記膀胱癌が、BCGレフラクティブまたはBCG抵抗性である、請求項1〜3のいずれか一項に記載の免疫複合体。
- 前記scFvが、配列番号3に対する相同性が少なくとも80%であるアミノ酸配列を含むヒト化scFvである、請求項1〜4のいずれか一項に記載の免疫複合体。
- 前記Pseudomonas属外毒素Aの切断型形態が、配列番号11に対する相同性が少なくとも80%であるアミノ酸配列を含む、請求項1〜5のいずれか一項に記載の免疫複合体。
- 前記scFvヒト化抗体が、配列番号10に対する相同性が少なくとも80%であるアミノ酸配列を含むペプチドリンカーによって前記Pseudomonas属外毒素Aの切断型形態に接続している、請求項1〜6のいずれか一項に記載の免疫複合体。
- 前記免疫複合体が、前記対象に、1用量あたり10mg〜60mgの用量レベルにて投与される、請求項1〜7のいずれか一項に記載の免疫複合体。
- 前記免疫複合体が、膀胱中への滴下注入によって投与され:
(a)前記免疫複合体が膀胱内に2時間保持される;あるいは
(b)前記免疫複合体が膀胱内にある間、前記対象が、立位、腹臥位、背臥位、ならびに左側臥位および右側臥位の姿勢にあり、任意に、前記対象が、各姿勢に、1姿勢あたり少なくとも15分間ある;
請求項1〜8のいずれか一項に記載の免疫複合体。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562132246P | 2015-03-12 | 2015-03-12 | |
US62/132,246 | 2015-03-12 | ||
US201562267385P | 2015-12-15 | 2015-12-15 | |
US62/267,385 | 2015-12-15 | ||
PCT/US2016/022077 WO2016145349A1 (en) | 2015-03-12 | 2016-03-11 | Methods of treatment for epcam positive bladder cancer |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018509423A JP2018509423A (ja) | 2018-04-05 |
JP2018509423A5 true JP2018509423A5 (ja) | 2019-04-18 |
JP6824183B2 JP6824183B2 (ja) | 2021-02-03 |
Family
ID=56879840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017548144A Active JP6824183B2 (ja) | 2015-03-12 | 2016-03-11 | Epcam陽性膀胱癌の処置方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10576163B2 (ja) |
EP (1) | EP3268040A4 (ja) |
JP (1) | JP6824183B2 (ja) |
CN (1) | CN108513547A (ja) |
AU (1) | AU2016228755B2 (ja) |
CA (1) | CA2979394A1 (ja) |
HK (1) | HK1249020A1 (ja) |
WO (1) | WO2016145349A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10576163B2 (en) | 2015-03-12 | 2020-03-03 | Viventia Bio Inc. | Methods of treatment for EpCAM positive bladder cancer |
WO2016145354A1 (en) | 2015-03-12 | 2016-09-15 | Viventia Bio Inc. | Dosing strategies for targeting epcam positive bladder cancer |
TW202029980A (zh) * | 2018-10-26 | 2020-08-16 | 美商免疫遺傳股份有限公司 | E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途 |
CN110804643B (zh) * | 2019-10-29 | 2022-06-21 | 同济大学 | 一种体外评价卡介苗对中性粒细胞活性影响的方法 |
WO2023141236A2 (en) * | 2022-01-19 | 2023-07-27 | Istari Oncology, Inc. | Methods for treating bladder cancers by intravesical instillation of a chimeric poliovirus |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5082767A (en) | 1989-02-27 | 1992-01-21 | Hatfield G Wesley | Codon pair utilization |
IL98528A0 (en) | 1990-06-21 | 1992-07-15 | Merck & Co Inc | Pharmaceutical compositions containing hybrid for killing bladder cancer cells |
US20030148463A1 (en) | 1997-04-14 | 2003-08-07 | Micromet Ag | Novel method for the production of anti-human antigen receptors and uses thereof |
GB9709421D0 (en) | 1997-05-10 | 1997-07-02 | Zeneca Ltd | Chemical compounds |
EP0975762B1 (en) | 1997-06-06 | 2011-10-05 | PanGenetics B.V. | Type-1 ribosome-inactivating protein |
EP1489100B1 (en) | 1997-12-08 | 2016-06-15 | Merck Patent GmbH | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
US6280742B1 (en) | 1998-06-17 | 2001-08-28 | Zonagen, Inc. | Methods and materials for the treatment of prostatic carcinoma |
CA2369622C (en) | 1999-04-09 | 2011-06-14 | Universitat Zurich | Novel method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment |
GB9911569D0 (en) | 1999-05-18 | 1999-07-21 | Oxford Biomedica Ltd | Antibodies |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US6969517B2 (en) | 2001-05-03 | 2005-11-29 | Emd Lexigen Research Center Corp. | Recombinant tumor specific antibody and use thereof |
US20030148950A1 (en) | 2001-10-09 | 2003-08-07 | Li Xin | Kringle domain 1 of human hepatocyte growth factor and uses therefor |
EP1448780A4 (en) | 2001-10-15 | 2005-08-31 | Immunomedics Inc | DIRECTLY TARGETED BONDING PROTEINS |
US20040022726A1 (en) * | 2002-06-03 | 2004-02-05 | Goldenberg David M. | Methods and compositions for intravesical therapy of bladder cancer |
SI21272A (sl) | 2002-07-31 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Sintetski gen za humani granulocitne kolonije stimulirajoči dejavnik za ekspresijo v E. coli |
CA2424255A1 (en) | 2003-03-26 | 2004-09-26 | Claudio Di Paolo | Immunotoxins |
EP2382990B1 (en) | 2003-04-30 | 2014-09-17 | Universität Zürich | Methods for treating cancer using an immunotoxin |
KR101165867B1 (ko) | 2004-03-19 | 2012-07-13 | 메르크 파텐트 게엠베하 | 변형 부가닌 단백질, 그 세포독소 및 이의 생산방법과 용도 |
NZ552476A (en) | 2004-06-10 | 2009-09-25 | Viventia Biotech Inc | Tumor specific antibody |
US20090171317A1 (en) * | 2006-03-10 | 2009-07-02 | Ebrahim Versi | Self-Catheterization Device To Administes Compounds To The Bladder |
CA2668017A1 (en) * | 2006-10-30 | 2008-05-08 | Viventia Biotech Inc. | Improved conjugates |
WO2008128330A1 (en) | 2007-04-19 | 2008-10-30 | Viventia Biotech Inc. | Optimized nucleotide sequences of vb6-845 for expression of recombinant proteins |
US8318472B2 (en) | 2007-09-27 | 2012-11-27 | Viventia Biotechnologies Inc. | Optimized nucleic acid sequences for the expression of VB4-845 |
CA2618163A1 (en) | 2008-02-07 | 2009-08-07 | K. W. Michael Siu | Head and neck cancer biomarkers |
CA2756246A1 (en) | 2009-04-08 | 2010-10-14 | Heinz Faulstich | Amatoxin-armed target-binding moieties for the treatment of cancer |
GB0909904D0 (en) | 2009-06-09 | 2009-07-22 | Affitech As | Product |
WO2011116387A1 (en) | 2010-03-19 | 2011-09-22 | Tetragenetics, Inc. | Production of aglycosylated monoclonal antibodies in ciliates |
US20140193436A1 (en) | 2011-06-24 | 2014-07-10 | Centrose, Llc | Extracellular targeted drug conjugates |
US20160060352A1 (en) | 2013-04-12 | 2016-03-03 | Viventia Bio Inc. | Compositions and methods for detection and treatment of hepatocellular carcinoma |
US20160136211A1 (en) * | 2013-06-17 | 2016-05-19 | Viralytics Limited | Methods for the treatment of bladder cancer |
JP2017504621A (ja) | 2013-10-02 | 2017-02-09 | ヴィヴェンティア バイオ インコーポレイテッド | 抗epcam抗体及び使用方法 |
US10576163B2 (en) | 2015-03-12 | 2020-03-03 | Viventia Bio Inc. | Methods of treatment for EpCAM positive bladder cancer |
WO2016145354A1 (en) | 2015-03-12 | 2016-09-15 | Viventia Bio Inc. | Dosing strategies for targeting epcam positive bladder cancer |
WO2017040801A2 (en) | 2015-09-02 | 2017-03-09 | Viventia Bio Inc. | Methods for making and using an immunoconjugate for the treatment of cancer |
-
2016
- 2016-03-11 US US15/557,371 patent/US10576163B2/en active Active
- 2016-03-11 EP EP16762627.4A patent/EP3268040A4/en not_active Withdrawn
- 2016-03-11 AU AU2016228755A patent/AU2016228755B2/en active Active
- 2016-03-11 CA CA2979394A patent/CA2979394A1/en active Pending
- 2016-03-11 CN CN201680027431.4A patent/CN108513547A/zh active Pending
- 2016-03-11 JP JP2017548144A patent/JP6824183B2/ja active Active
- 2016-03-11 WO PCT/US2016/022077 patent/WO2016145349A1/en active Application Filing
-
2018
- 2018-07-05 HK HK18108683.5A patent/HK1249020A1/zh unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018509423A5 (ja) | ||
JP2017506217A5 (ja) | ||
JP2019511222A5 (ja) | ||
JP2019527706A5 (ja) | ||
RU2019106663A (ru) | Комбинированная терапия рака | |
JP2016502515A5 (ja) | ||
JP2018502120A5 (ja) | ||
JP2018535204A5 (ja) | ||
JP2016505635A5 (ja) | ||
MX2023002554A (es) | Anticuerpos anti-il-1r3 humanizados. | |
RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
JP2018512402A5 (ja) | ||
RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
MX2019012884A (es) | Terapia de combinacion. | |
JP2019510001A5 (ja) | ||
JP2016528247A5 (ja) | ||
JP2014158469A5 (ja) | ||
JP2014509841A5 (ja) | ||
JP2017523184A5 (ja) | ||
JP2016529255A5 (ja) | ||
JP2016539946A5 (ja) | ||
JP2016535009A5 (ja) | ||
JP2019510739A5 (ja) | ||
JP2015505843A5 (ja) | ||
JP2016521712A5 (ja) |